INHIBRX BIOSCIENCES INC (INBX) — insider trading
Health Care · NASDAQ
INHIBRX BIOSCIENCES INC (INBX) has 14 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 14 (latest 2026-06-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | MANHARD KIMBERLY | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-03 | FORSYTH DOUGLAS | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Kayyem Jon Faiz | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Vuori Kristiina MD | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-04-24 | Matly David | Officer (President) | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities GP LLC; Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon | 10% owner | Open-market sale | 25,042 | $32.25 | $807.6K | Form 4 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities GP LLC; Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon | 10% owner | Open-market sale | 16,315 | $32.25 | $526.2K | Form 4 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities GP LLC; Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon | 10% owner | Open-market sale | 308,643 | $32.25 | $9.95M | Form 4 |
| 2025-05-28 | FORSYTH DOUGLAS | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2025-05-28 | Kayyem Jon Faiz | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2025-05-28 | Vuori Kristiina MD | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2025-05-28 | MANHARD KIMBERLY | Director | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2025-04-01 | Matly David | Officer (President) | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2025-04-01 | Deck Kelly | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 15,000 | $0.00 | $0 | Form 4 |
Ask the chat about INBX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: INHIBRX BIOSCIENCES INC (INBX).
Last updated 2026-06-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.